1 Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009;29:938-46.10.1111/j.1365-2036.2009.03960.x 19220208
2 Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010;16:e228-34.21250399
3 Pasina L, Nobili A, Tettamanti M, etal. REPOSI Investigators. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011;22:205-10.10.1016/j.ejim.2010.11.009 21402255
4 Lanas A, Boers M, Nuevo J. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann Rheum Dis 2015;74:675-81.10.1136/annrheumdis-2013-204155 24351518
5 van den Bemt PM, Chaaouit N, van Lieshout EM, Verhofstad MH. Noncompliance with guidelines on proton pump inhibitor prescription as gastroprotection in hospitalized surgical patients who are prescribed NSAIDs. Eur J Gastroenterol Hepatol 2016;28:857-62. 10.1097/MEG.0000000000000634 27046006
6 Kim JJ, Lee JS, Olafsson S, Laine L. Low adherence to Helicobacter pylori testing in hospitalized patients with bleeding peptic ulcer disease. Helicobacter 2014;19:98-104.10.1111/hel.12114 24617668
7 Murakami TT, Scranton RA, Brown HE, etal . Management of Helicobacter Pylori in the United States: Results from a national survey of gastroenterology physicians. Prev Med 2017;100:216-22. 10.1016/j.ypmed.2017.04.021 28457713
9 Boltin D, Kimchi N, Dickman R, Gingold- Belfer R, Niv Y, Birkenfeld S. Attitudes and practice related to Helicobacter pylori infection among primary care physicians. Eur J Gastroenterol Hepatol 2016;28:1035-40. 10.1097/MEG.0000000000000659 27167452
10 Werdmuller BF, van der Putten AB, Loffeld RJ. The clinical presentation of peptic ulcer disease. Neth J Med 1997;50:115-9. 10.1016/S0300-2977(96)00075-7 9121595
11 Cai S, García Rodríguez LA, Massó-González EL, Hernández-Díaz S. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther 2009;30:1039-48. 10.1111/j.1365-2036.2009.04131.x 19709097
12 Aro P, Storskrubb T, Ronkainen J, etal . Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 2006;163:1025-34.10.1093/aje/kwj129 16554343
13 Agréus L, Hellström PM, Talley NJ, etal . Towards a healthy stomach? Helicobacter pylori prevalence has dramatically decreased over 23 years in adults in a Swedish community. United European Gastroenterol J 2016;4:686-96. 10.1177/2050640615623369 27733911
14 Leow AH, Lim YY, Liew WC, Goh KL. Time trends in upper gastrointestinal diseases and Helicobacter pylori infection in a multiracial Asian population—a 20-year experience over three time periods. Aliment Pharmacol Ther 2016;43:831-7. 10.1111/apt.13550 26847417
15 Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 1985;142:439-44.3982346
16 Graham DY, Klein PD, Opekun AR, Boutton TW. Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the [13C]urea breath test in normal subjects and patients with peptic ulcer disease. J Infect Dis 1988;157:777-80.10.1093/infdis/157.4.777 3346569
17 Hansson LE, Nyrén O, Hsing AW, etal . The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996;335:242-9.10.1056/NEJM199607253350404 8657240
18 Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174.10.1136/bmj.g3174 24846275
19 Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009;30:791-815. 10.1111/j.1365-2036.2009.04105.x 19706147
20 Konturek J, Bielanski W, Plonka M, etal . Helicobacter pylori, non-steroidal anti-inflammatory drugs and smoking in risk pattern of gastroduodenal ulcers. Scand J Gastroenterol 2003;38:923-30. 10.1080/00365520310004696 14531527
21 Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749-54. 10.1056/NEJM199209103271101 1501650
22 Yeomans ND, Lanas AI, Talley NJ, etal . Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801. 10.1111/j.1365-2036.2005.02649.x 16225488
23 Rafaniello C, Ferrajolo C, Sullo MG, etal . Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacol Res 2016;104:108-14. 10.1016/j.phrs.2015.12.026 26739516
24 Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf 2014;23:43-50. 10.1002/pds.3463 23723142
25 Silverstein FE, Faich G, Goldstein JL, etal . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55. 10.1001/jama.284.10.1247 10979111
26 Coblijn UK, Goucham AB, Lagarde SM, Kuiken SD, van Wagensveld BA. Development of ulcer disease after Roux-en-Y gastric bypass, incidence, risk factors, and patient presentation: a systematic review. Obes Surg 2014;24:299-309.
10.1007/s11695-013-1118-5 24234733
27 El-Hayek K, Timratana P, Shimizu H, Chand B. Marginal ulcer after Roux-en-Y gastric bypass: what have we really learned?Surg Endosc 2012;26:2789-96.10.1007/s00464-012-2280-x 22543994
28 Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17. 10.1097/00004836-199701000-00002 9013343
29 Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hallas J. There is an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers: a population-based case-control study. Aliment Pharmacol Ther 2010;32:1383-91.10.1111/j.1365-2036.2010.04472.x 21050241
30 Jiang HY, Chen HZ, Hu XJ, etal . Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015;13:42-50.e3. 10.1016/j.cgh.2014.06.021 24993365
31 Krag M, Perner A, Wetterslev J, etal. SUP-ICU co-authors. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med 2015;41:833-45. 10.1007/s00134-015-3725-1 25860444
32 Tamura J, Arakaki S, Shibata D, Maeshiro T. Cytomegalovirus-associated gastric ulcer: a diagnostic challenge in a patient of fulminant hepatitis with steroid pulse therapy. BMJ Case Rep 2013;2013. 10.1136/bcr-2013-010501 23997079
33 Levenstein S, Rosenstock S, Jacobsen RK, et al. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol 2015;13:498-506 e1.
34 Friedman GD, Siegelaub AB, Seltzer CC. Cigarettes, alcohol, coffee and peptic ulcer. N Engl J Med 1974;290:469-73. 10.1056/NEJM197402282900901 4810814
35 Shimamoto T, Yamamichi N, Kodashima S, etal . No association of coffee consumption with gastric ulcer, duodenal ulcer, reflux esophagitis, and non-erosive reflux disease: a cross-sectional study of 8,013 healthy subjects in Japan. PLoS One 2013;8:e65996.10.1371/journal.pone.0065996 23776588
36 Chung CS, Chiang TH, Lee YC. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J Intern Med 2015;30:559-70.10.3904/kjim.2015.30.5.559 26354049
37 Charpignon C, Lesgourgues B, Pariente A, etal. Group de l’Observatoire National des Ulcères de l’Association Nationale des HépatoGastroentérologues des Hôpitaux Généraux (ANGH). Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment Pharmacol Ther 2013;38:946-54.10.1111/apt.12465 23981105
38 Freston JW. Review article: role of proton pump inhibitors in non-H. pylori-related ulcers. Aliment Pharmacol Ther 2001;15(Suppl 2):2-5.10.1046/j.1365-2036.2001.00114.x 11556873
39 National Institute for Health and Care Excellence. The management of dyspepsia in adult patients in primary care, guidelines from National Institute for Health and Clinical Excellence. London: NICE, 2004. https://www.nice.org.uk/guidance/cg17
40 Gralnek IM, Dumonceau JM, Kuipers EJ, etal . Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:a1-46. 10.1055/s-0034-1393172 26417980
41 National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Guidelines from National Institute for Health and Clinical Excellence. NICE guidelines 2015. https://www.nice.org.uk/guidance/ng12
42 Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 2011;84:102-13. 10.1159/000323958 21494041
43 Wong GL, Wong VW, Chan Y, etal . High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009;137:525-31. 10.1053/j.gastro.2009.05.006 19445937
44 Hung LC, Ching JY, Sung JJ, etal . Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005;128:1845-50. 10.1053/j.gastro.2005.03.026 15940620
45 Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol 2017;112:988-1013.10.1038/ajg.2017.154 28631728
46 Agréus L, Talley NJ, Jones M. Value of the “test & treat” strategy for uninvestigated dyspepsia at low prevalence rates of Helicobacter pylori in the population. Helicobacter 2016;21:186-91. 10.1111/hel.12267 26347458
47 Saniee P, Shahreza S, Siavoshi F. Negative effect of proton-pump inhibitors (PPIs) on Helicobacter pylori growth, morphology, and urease test and recovery after PPI removal–an in vitro study. Helicobacter 2016;21:143-52. 10.1111/hel.12246 26222264
48 Leung WK, Hung LC, Kwok CK, Leong RW, Ng DK, Sung JJ. Follow up of serial urea breath test results in patients after consumption of antibiotics for non-gastric infections.
World J Gastroenterol 2002;8:703-6. 10.3748/wjg.v8.i4.703 12174382
49 Griffin SM, Bowrey DJ, Allum WH. Upper gastrointestinal surgeons comment on NICE dyspepsia guidelines. BMJ 2005;330:308-9. 10.1136/bmj.330.7486.308-b 15695281
50 Scally B, Emberson JR, Spata E, etal . Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3:231-41.10.1016/S2468-1253(18)30037-2 29475806
51 Nyssen OP, McNicholl AG, Megraud F, etal . Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016;(6):CD009034.27351542
52 Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2004;(4):CD003840.15495066
53 Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med 2017;37:19-24.
10.1016/j.ejim.2016.10.007 27784575 54 Ntaios G, Chatzinikolaou A, Kaiafa G, Savopoulos C, Hatzitolios A, Karamitsos D. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med 2009;20:171-3. 10.1016/j.ejim.2007.10.020 19327607
55 Al Khaja KAJ, Veeramuthu S, Isa HA, Sequeira RP. Prescription audit of NSAIDs and gastroprotective strategy in elderly in primary care. Int J Risk Saf Med 2017;29:57-68. 10.3233/JRS-170742 28885223
56 Hussain S, Siddiqui AN, Habib A, Hussain MS, Najmi AK. Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis. Rheumatol Int 2018;38:1999-2014. 10.1007/s00296-018-4142-x 30159775
57 Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ 2018;27:443-50. 10.1016/j.hlc.2017.10.020 29233498}
58 Haenisch B, von Holt K, Wiese B, etal . Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 2015;265:419-28.10.1007/s00406-014-0554-0 25341874
59 Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open 2017;7:e017739. 10.1136/bmjopen-2017-017739 29084798
60 Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018;67:28-35. 10.1136/gutjnl-2017-314605 29089382
61 Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side effects of long-term proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol 2018;123:114-21.10.1111/bcpt.13023 29658189
62 Graham DY, Agrawal NM, Campbell DR, etal. NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;162:169-75.10.1001/archinte.162.2.169 11802750
63 Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Muñoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004;19:617-29.10.1111/j.1365-2036.2004.01898.x 15023164
64 Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006;2:CD003840. 10.1002/14651858.CD003840.pub4 16625592 65 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter 2017;22. 10.1111/hel.12392. 28464347
66 Liou JM, Chen CC, Chen MJ, etal. Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-13. 10.1016/S0140-6736(12)61579-7 23158886
67 Malfertheiner P, Megraud F, O’Morain CA, etal. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30.10.1136/gutjnl-2016-312288 27707777
68 Ross SJ, Elgendy IY, Bavry AA. Cardiovascular safety and bleeding risk associated with nonsteroidal anti-inflammatory medications in patients with cardiovascular disease. Curr Cardiol Rep 2017;19:8. 10.1007/s11886-017-0814-5 28138824
69 Derogar M, Sandblom G, Lundell L, etal . Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin Gastroenterol Hepatol 2013;11:38-42. 10.1016/j.cgh.2012.08.034 22975385
70 Sung JJ, Lau JY, Ching JY, etal . Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;152:1-9. 10.7326/0003-4819-152-1-201001050-00179 19949136
71 Lanza FL, Chan FK, Quigley EMPractice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38. 10.1038/ajg.2009.115 19240698
72 Rostom A, Dube C, Wells G, etal . Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;(4):CD002296.12519573
73 Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(Suppl 1):9-14.10.1111/j.1365-2036.1995.tb00778.x 7495945
74 Ng FH, Wong SY, Lam KF, etal . Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010;138:82-8.10.1053/j.gastro.2009.09.063 19837071
75 Gumbs AA, Duffy AJ, Bell RL. Incidence and management of marginal ulceration after laparoscopic Roux-Y gastric bypass. Surg Obesity Rel Dis 2006;2:460-3.
76 Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;60:1327-35. 10.1136/gut.2010.228437 21490373
77 Sverdén E, Mattsson F, Lindström D, Sondén A, Lu Y, Lagergren J. Transcathete arterial embolization compared with surgery for uncontrolled peptic ulcer bleeding: a population-based cohort study. Ann Surg 2019;269:304-9.10.1097/SLA.0000000000002565 29064894
78 Chung KT, Shelat VG. Perforated peptic ulcer—an update. World J Gastrointest Surg 2017;9:1-12. 10.4240/wjgs.v9.i1.1 28138363
79 Heo J, Jung MK. Safety and efficacy of a partially covered self-expandable metal stent in benign pyloric obstruction. World J Gastroenterol 2014;20:16721-5. 10.3748/wjg.v20.i44.16721 25469043
80 Tulassay Z, Stolte M, Sjölund M, etal . Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol 2008;20:526-36.
10.1097/MEG.0b013e3282f427ac. 18467912 81 Podolsky I, Storms PR, Richardson CT, Peterson WL, Fordtran JS. Gastric adenocarcinoma masquerading endoscopically as benign gastric ulcer. A five-year experience. Dig Dis Sci 1988;33:1057-63. 10.1007/BF01535778 3409791
82 Sugano K, Tack J, Kuipers EJ, etal. faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-67. 10.1136/gutjnl-2015-309252 26187502
8 Assessment SSCoHT. Blödande magsår. En systematisk litteraturöversikt - SBU: Swedish Council on Health Technology Assessment. SBU, 2011.
Comentarios
Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí
Eficacia del triple tratamiento para la infección por Helicobacter pylori